83 results
S-8
NGNE
Neurogene Inc
20 Feb 24
Registration of securities for employees
4:16pm
circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act. The Registrant’s organizational documents
8-K
EX-10.23
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
not owe Employee any other amounts. Employee acknowledges that Employee must promptly submit for reimbursement all final outstanding expenses, if any.
3
8-K
EX-10.29
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
days of completing the Series A, the Company will confirm the specific detail of the award to the Consultant.
3.3 Reimbursement of Expenses
8-K
EX-10.24
xd39tm95yvl f2f
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-3.3
zojfmp
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
8-K
EX-10.26
jdemt
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
S-4/A
1qfub69 4wgd3a5gzl
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.31
f90nq7epcopd
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.29
4kufcxga 4v6y
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.35
ocrxxl8pztereohl
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4
o6gfssdblp
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
425
c4eh hgezrz1hacw0
18 Jul 23
Business combination disclosure
8:37am
8-K
EX-2.1
s4sq6dbv jha
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am